MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-01-2026
Tilray Operating Income 2011-2026 | TLRY
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.37 B | -610 M | -132 M | -104 M | -304 M | -57.8 M | -7.5 M | -7.05 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.05 M | -1.37 B | -324 M |
Quarterly Operating Income Tilray
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.4 M | -22.3 M | 2.09 M | - | -760 M | -42.2 M | -36.6 M | - | -82.1 M | -41.8 M | -34.4 M | - | -1.21 B | -51.8 M | -21.2 M | -73 M | -18.1 M | -55.5 M | -69.4 M | -125 M | -73.3 M | -26 M | -32.8 M | -75.8 M | -71.2 M | -217 M | -23.8 M | -33 M | -28.4 M | -22.9 M | -20 M | -11 M | -3.74 M | -2.61 M | -2.18 M | -2.32 M | -388 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 M | -1.21 B | -97.4 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.23 | 4.53 % | $ 45.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.9 | 1.37 % | $ 2.15 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 41.5 | 2.09 % | $ 1.53 B | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.14 | -0.87 % | $ 123 M | Canada |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 24.72 | 3.6 % | $ 1.14 B | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.46 | -3.95 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.69 | 3.53 % | $ 302 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.51 | - | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.81 | 2.2 % | $ 451 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.44 | -1.21 % | $ 329 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.5 | -1.96 % | $ 329 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.79 | 5.76 % | $ 3.41 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.01 | -0.06 % | $ 115 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.48 | 6.86 % | $ 295 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 1.11 | 5.71 % | $ 55.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 8.63 | 2.86 % | $ 755 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.3 | 4.07 % | $ 2.85 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.68 | 4.78 % | $ 17.6 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.66 | 1.39 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.91 | -0.27 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.67 | 1.67 % | $ 2.88 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.07 | -0.48 % | $ 23.9 M | USA |